Intraventricular Chemotherapy for Leptomeningeal Carcinoma

[1]  J. B. Blacklock,et al.  Control of spasticity by implantable continuous flow morphine pump. , 1985, Neurosurgery.

[2]  Nurchi Gc.  Use of intraventricular and intrathecal morphine in intractable pain associated with cancer. , 1984 .

[3]  B. N. French,et al.  Intrathecal morphine for pelvic and sacral pain caused by cancer. , 1984, Surgical neurology.

[4]  D. Poplack,et al.  Cytosine arabinoside cerebrospinal fluid kinetics , 1984, Clinical pharmacology and therapeutics.

[5]  G. Curt,et al.  Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. , 1984, Cancer research.

[6]  D. Trump,et al.  Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. , 1982, The American journal of medicine.

[7]  G. Hortobagyi,et al.  Treatment for meningeal carcinomatosis in breast cancer , 1982, Cancer.

[8]  K. Kim,et al.  Spinal leptomeningeal infiltration by systemic cancer: myelographic features. , 1982, AJR. American journal of roentgenology.

[9]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[10]  R. Makuch,et al.  Carcinomatous Leptomeningitis in Small Cell Lung Cancer: A Clinicopathologic Review of the National Cancer Institute Experience , 1982, Medicine.

[11]  V. Sondak,et al.  Leptomeningeal spread of breast cancer: Report of case and review of the literature , 1981, Cancer.

[12]  H. Greenberg,et al.  Implanted system for intraventricular drug infusion in central nervous system tumors. , 1981, Cancer treatment reports.

[13]  M. Fleisher,et al.  Cerebrospinal fluid biochemical markers of central nervous system metastases , 1980, Annals of neurology.

[14]  J. Aisner,et al.  Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival. , 1979, Acta cytologica.

[15]  H. Abelson.  Methotrexate and central nervous system toxicity. , 1978, Cancer treatment reports.

[16]  D. Enzmann,et al.  Computed tomography in leptomeningeal spread of tumor. , 1978, Journal of computer assisted tomography.

[17]  V. Vaitkevicius,et al.  Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival , 1978, Cancer.

[18]  R. Price,et al.  The central nervous system in childhood leukemia. III. mineralizing microangiopathy and dystrophic calcification , 1978, Cancer.

[19]  B. Yap,et al.  Meningeal carcinomatosis in breast cancer , 1978, Cancer.

[20]  W. Schoene,et al.  Multifocal pontine lesions in cancer patients treated with chemotherapy and cns radiotherapy , 1978, Cancer.

[21]  R. Simon,et al.  "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. , 1978, Blood.

[22]  C. Terrence,et al.  Hearing loss in carcinomatous meningitis , 1978, The Journal of Laryngology & Otology.

[23]  Bleyer Wa.  Current status of intrathecal chemotherapy for human meningeal neoplasms. , 1977 .

[24]  C. Patlak,et al.  Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. , 1977, Cancer treatment reports.

[25]  C. Spurr,et al.  Prophylactic cranial irradiation in small cell carcinoma of the lung: A Randomized Study , 1977 .

[26]  W. Ensminger,et al.  The prevention of methotrexate toxicity by thymidine infusions in humans. , 1977, Cancer research.

[27]  P. Gutin,et al.  Intrathecal n, n′, n′‐triethylenethiophosphoramide [thio‐tepa (NSC 6396)] in the treatment of malignant meningeal disease. Phase I‐II study , 1976, Cancer.

[28]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[29]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[30]  R. Price,et al.  The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy , 1975, Cancer.

[31]  M. Herman,et al.  Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma , 1975, Cancer.

[32]  A. J. Dale,et al.  Meningeal carcinomatosis. Clinical manifestations. , 1974, Archives of neurology.

[33]  J. Posner,et al.  Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. , 1974, Archives of neurology.

[34]  J. L. Smith,et al.  Carcinomatous optic neuropathy. , 1973, American journal of ophthalmology.

[35]  B. Chabner,et al.  Drug Actions Interactions & Reactions , 1973, The New England journal of medicine.

[36]  B. Chabner,et al.  Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. , 1973, The Journal of clinical investigation.

[37]  P. Altrocchi,et al.  Blindness and meningeal carcinomatosis. , 1972, Archives of ophthalmology.

[38]  E. Gehan,et al.  Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs. intravenous bis-nitrosourea. , 1971, Blood.

[39]  R. Jampel,et al.  Ocular signs in diffuse carcinomatous meningitis. , 1961, American journal of ophthalmology.

[40]  W. Shapiro,et al.  Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. , 1983, Cancer research.

[41]  D. Kufe,et al.  Treatment of central nervous system tumors with methotrexate. , 1981, Cancer treatment reports.

[42]  M. Corder,et al.  Monitoring central nervous system methotrexate levels via subcutaneous reservoir. Sources of errors in sampling and their avoidance. , 1980, Cancer clinical trials.

[43]  M. K. Rubinstein.  Cranial mononeuropathy as the first sign of intracranial metastases. , 1969, Annals of internal medicine.